Score Overview
Atara Biotherapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 3M to $ 120M and net income went from -$ 306M to $ 32M. Revenue increased in 2 of those 5 years; net income in 3.
Atara Biotherapeutics Inc currently holds a 5-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 9.22 | — |
1 Year2025-08-12 | $ 11.54 | -20.06% |
5 Years2021-08-12 | $ 314.00 | -97.06% |
10 Years2016-08-12 | $ 530.50 | -98.26% |
All Time2014-10-16 | $ 266.25 | -96.54% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | All Time2014-10-16 |
|---|---|---|---|---|---|
| Price | $ 9.22 | $ 11.54 | $ 314.00 | $ 530.50 | $ 266.25 |
| Return | — | -20.06% | -97.06% | -98.26% | -96.54% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 23M | -$ 9M | $ 8M |
| 2025 | $ 120M | $ 32M | $ 8M |
| 2024 | $ 128M | -$ 85M | $ 42M |
| 2023 | $ 8M | -$ 276M | $ 51M |
| 2022 | $ 63M | -$ 228M | $ 242M |
| 2021 | $ 20M | -$ 340M | $ 371M |
| 2020 | $ 3M | -$ 306M | $ 500M |
| 2019 | $ 0.00 | -$ 290M | $ 259M |
| 2018 | $ 0.00 | -$ 230M | $ 309M |
| 2017 | $ 0.00 | -$ 119M | $ 166M |
| 2016 | $ 0.00 | -$ 79M | $ 255M |
| 2015 | $ 0.00 | -$ 57M | $ 320M |
| IPO2014 | $ 0.00 | -$ 28M | $ 104M |
Explore beyond ATRA
You're looking at Atara Biotherapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
